| Schizophrenia |
1 |
1 |
| Antipsychotics |
0 |
0.99 |
| Pneumonia |
0 |
0.64 |
| Patient Safety |
0 |
0.44 |
| Respiratory Tract Infections |
0 |
0.98 |
| COVID-19 Vaccine |
0 |
0.43 |
| COVID-19 |
0 |
0.4 |
| Neutropenia |
0 |
0.35 |
| Adverse Effects |
0 |
0.29 |
| Influenza |
0 |
0.22 |
| Vaccines |
0 |
0.22 |
| Ileus |
0 |
0.15 |
| Immunization |
0 |
0.15 |
| Neutrophils |
0 |
0.15 |
| Young Adult |
0 |
0.15 |
| Risk Evaluation and Mitigation Strategies |
0 |
0.13 |
| Revenue and Practice Management |
0 |
0.11 |
| Agranulocytosis |
0 |
0.07 |
| Blood |
0 |
0.07 |
| Clinical Guidelines |
0 |
0.07 |
| Continuity of Care |
0 |
0.07 |
| Drug and Treatment Safety |
0 |
0.07 |
| Exercise |
0 |
0.07 |
| Face |
0 |
0.07 |
| Food and Drug Administration (FDA) |
0 |
0.07 |
| Health Care Economics |
0 |
0.07 |
| Hospital |
0 |
0.07 |
| Mental Illness |
0 |
0.07 |
| Myocarditis |
0 |
0.07 |
| Pandemic |
0 |
0.07 |
| Schizoaffective Disorder |
0 |
0.07 |
| Sedative |
0 |
0.07 |